hepatocellular carcinoma (hcc)

Droxinostat (NS 41080) is a selective HDAC inhibitor, primarily targeting HDACs 6 and 8 with IC50 values of 2.47 μM and 1.46 μM, respectively. It is over 8-fold more selective against HDAC3 and shows no inhibition for HDAC1, 2, 4, 5, 7, 9, and 10.

Rosiglitazone (BRL49653) is a PPARγ agonist, TRPC5 activator, and TRPM3 inhibitor with oral activity. Rosiglitazone is also a hypoglycemic agent and a thiazolidinedione insulin sensitizer.

Palbociclib (PD 0332991) is a CDK inhibitor that inhibits CDK4 and CDK6 (IC50=11/16 nM) and is orally active. Palbociclib has anti-tumorigenic activity and has investigational potential for use in ER-positive and HER2-negative breast cancer.

Vacquinol-1 is an MKK4 activator, which rapidly and selectively induces glioma cell death.

Triglycidyl isocyanurate (Teroxirone) is a triazene triepoxide with antineoplastic and antiangiogenic activity. It inhibits growth of human non-small cell lung cancer cells by activating p53. Triglycidyl isocyanurate alkylates and cross-links DNA, thereby inhibiting DNA replication. It induces cell apoptosis and can be used for cancer research[1][2]. Triglycidyl isocyanurate is also used in various polyester powder coatings in the metal finishing industry.

Palbociclib monohydrochloride (PD 0332991 hydrochloride) is a selective inhibitor of CDK4/6 (IC50s: 11/16 nM). It exhibits no inhibition against a panel of 36 additional protein kinases.

Rosiglitazone hydrochloride (BRL-49653 HCl) is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.

Silymarin is a natural polyphenolic flavonolignan mixture extracted from the seeds of Silybum marianum. It can inhibit tumor cell proliferation and angiogenesis, and improve insulin resistance, thus being widely used in liver disease-related research and adjuvant applications. Studies have shown that silymarin exhibits inhibitory activity against the SARS-CoV-2 main protease, and it has potential research value in the mechanism-related studies of COVID-19.

Rubone (2'-Hydroxy-2,4,4',5,6'-pentamethoxychalcone), a natural product and a modulator of miR-34a (microRNA-34), upregulates miR-34a expression in a p53-dependent manner, which in turn downregulates the expression of downstream targets Bcl-2, cyclin-D1, CDK6, SIRT1, and FOXP1, thereby inhibiting tumor growth and reversal of hepatocellular carcinoma (HCC) and chemoresistance in prostate cancer.

FAPI-4 FAPI-4 is a fibroblast activating protein (FAP) inhibitor, a FAPI ligand, which shows strong liver uptake in PET imaging of primary liver cancer hepatocellular carcinoma (HCC) and is commonly used in PET imaging for the study of cancer.

PMED-1, a β-catenin inhibitor, effectively suppresses β-catenin activity in hepatoblastoma cells and various HCC (Hepatocellular Carcinoma) cells with IC50 values ranging from 4.87 to 32 μM. It impedes cell proliferation by disrupting the interaction between β-catenin and CREB-binding protein, thus affecting Wnt signaling pathways. PMED-1 is utilized in cancer research studies.

CV-4-26 (Compound 22) acts as a covalent inhibitor of TEAD. By inhibiting YAP/TEAD-driven transcription, it diminishes the expression of CTGF and CYR61. Furthermore, CV-4-26 impedes colony formation in Huh7 and HepG2 cells, inducing cell cycle arrest and apoptosis (apoptosis). This compound demonstrates anti-tumoral activity against hepatocellular carcinoma (HCC) and hepatoblastoma (HB).

CRI9 effectively inhibits the c-MET/PI3K/Akt/mTOR axis, suppressing the proliferation of hepatocellular carcinoma (HCC) cells. This compound exhibits potent cytotoxicity against HCC cells and induces apoptosis.

SET-171 is a JNK (c-Jun N-terminal kinase) inhibitor that exhibits significant anticancer activity by suppressing the expression of hepatic pyruvate kinase (PKL) and offers potential in regulating lipid metabolism. In antitumor studies, SET-171 shows notable cytotoxicity against human liver cancer cell lines HepG2 and Huh7, with IC50 values of 8.82 μM and 2.97 μM, respectively. Additionally, in research related to non-alcoholic fatty liver disease (NAFLD), SET-171 significantly reduces triglyceride (TAG) levels and inhibits the expression of proteins associated with steatosis. This compound holds promise for hepatocellular carcinoma (HCC) and NAFLD research.

API32 is a potent Pin1 inhibitor that interacts with the Pin1 PPIase domain. It effectively suppresses cell proliferation and migration, making it a promising candidate for research in hepatocellular carcinoma (HCC).

ZSNI-21 is a dual inhibitor targeting ADAM17 and HDAC2. It effectively suppresses the proliferation of Bel-7402 cells and exhibits significant anti-metastatic properties against HCC-LM3 cells, making it a promising candidate for hepatocellular carcinoma (HCC) research.

CIB-L43 is a high affinity and orally available TRBP inhibitor (KD = 4.78 nM), which can effectively inhibit the biosynthesis of oncogenic miR-21, increase the expression of PTEN and Smad7, and block the AKT and TGF-β signaling pathways to inhibit the proliferation and migration of hepatocellular carcinoma (HCC) cells.

AKR1C3-IN-15 (compound 30) is an effective and selective AKR1C3 inhibitor with an IC50 value of 5 nM. It enhances Sorafenib-induced ROS production, promotes apoptosis, and restores sensitivity to Sorafenib in hepatocellular carcinoma (HCC) models, as demonstrated in both in vitro and in vivo studies.

TRBP-IN-1 (Compound 13j) is an orally active inhibitor of TAR RNA-binding protein 2 (TRBP) with an IC50 of 12.72 μM. It exhibits significant anti-hepatocellular carcinoma (HCC) activity, effectively suppressing proliferation and metastasis of HCC cells [HCCLM3 cells (IC50: 18.96 μM) and SK-Hep-1 cells (IC50: 16.45 μM)]. TRBP-IN-1 modulates miRNA biosynthesis by targeting TRBP, inhibiting the expression of oncogenic miRNAs. It induces apoptosis and pyroptosis in HCC cells by decreasing miRNA levels. TRBP-IN-1 is suitable for research on targeted HCC therapy.

QC-182 is a potent p300/CBP PROTAC degrader. It reduces p300 protein levels in SK-HEP-1 cells with a DC50 of 93 nM. QC-182 effectively inhibits cell growth in SK-HEP-1 and JHH7 cell lines, with IC50 values of 0.733 μM and 0.477 μM, respectively. QC-182 is applicable for hepatocellular carcinoma (HCC) research.

FGFR4-IN-19 (compound 8B) is a potent covalent inhibitor of fibroblast growth factor receptor 4 (FGFR4) with an IC50 value of 1.2 nM. It achieves high efficiency and selectivity by covalently targeting the rare cysteine (C552) in the FGFR4 kinase domain. FGFR4-IN-19 is applicable for hepatocellular carcinoma (HCC) research.

c-Met degrader-1 (Compound H11) is an orally active c-Met degrader that operates via the ubiquitin-proteasome system. It exhibits anti-hepatocellular carcinoma (HCC) activity and hampers tumor growth in MHCC97H xenografts. Additionally, c-Met degrader-1 suppresses the proliferation of HCC cells, disrupts the cell cycle, and induces apoptosis. It may also potentially overcome resistance to Type I c-Met inhibitors.

DNH28 is a potent NF-κB and MAPK inhibitor with an IC50 value of 0.93 μM in HepG2 cells. It induces apoptosis by downregulating Bcl-2 and upregulating BAX and Cleaved-caspase-3 expression. DNH28 can arrest the cell cycle and inhibit cell migration, and is applicable for research in hepatocellular carcinoma (HCC).

ABT-002 is a molecular glue degrader that targets GSPT1 and NEK7, and it shows promise for research in hepatocellular carcinoma (HCC).